Zero Point Five Therapeutics

Zero Point Five Therapeutics, Inc.

10 Investors

Biotechnology

BALTIMORE, MD

Zero Point Five Therapeutics, Inc., also known as ZP5 Therapeutics, is a biotechnology company focused on developing effective treatments for neglected tropical diseases, particularly soil-transmitted helminthiasis (STH). The company aims to create accessible therapies for diseases that disproportionately affect marginalized communities worldwide, addressing a critical health crisis caused by intestinal parasitic infections.

Products & Team

ZP5-9676

PharmaceuticalsSeed

ZP5-9676 is a drug candidate based on flubendazole and is currently in Phase 3 clinical trials, aimed at treating infections caused by soil-transmitted helminths including hookworm, roundworm, and whipworm.

Value Proposition

ZP5-9676 addresses the crucial gap in effective treatments for STH infections in low-resource settings, aiming to reduce the burden of parasitic diseases and improve health outcomes.

Pain Points

The lack of effective, accessible treatments for NTDs, high prevalence of malnutrition and growth issues related to parasitic infections, and significant health disparities in low-income populations.

Targets multiple STH infectionsUndergoing Phase 3 clinical trialsSafe and effective treatment profile